Matt  Abernethy net worth and biography

Matt Abernethy Biography and Net Worth

Matthew C. Abernethy was appointed Chief Financial Officer in November 2017 and is responsible for leading corporate finance activities and commercial supply chain operations, as well as information technology and investor relations functions at Neurocrine Biosciences. Mr. Abernethy has over 15 years of experience in the financial sector and investor relations, with expertise in the healthcare industry. He joined Neurocrine Biosciences from Zimmer Biomet, where he held various positions from February 2009 to November 2017, including most recently, Vice President, Investor Relations and Treasurer and Vice President of Finance for the Americas and Global Product Engines. He began his career with KPMG LLP and is a certified public accountant. Mr. Abernethy earned his B.S. in Accounting and Business Administration from Grace College and an M.B.A. from the University of Chicago.

What is Matt Abernethy's net worth?

The estimated net worth of Matt Abernethy is at least $4.19 million as of February 13th, 2024. Mr. Abernethy owns 31,528 shares of Neurocrine Biosciences stock worth more than $4,192,909 as of April 16th. This net worth evaluation does not reflect any other investments that Mr. Abernethy may own. Additionally, Mr. Abernethy receives a salary of $1,040,000.00 as CFO at Neurocrine Biosciences. Learn More about Matt Abernethy's net worth.

How old is Matt Abernethy?

Mr. Abernethy is currently 43 years old. There are 8 older executives and no younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who is 66 years old. Learn More on Matt Abernethy's age.

What is Matt Abernethy's salary?

As the CFO of Neurocrine Biosciences, Inc., Mr. Abernethy earns $1,040,000.00 per year. The highest earning executive at Neurocrine Biosciences is Dr. Kevin C. Gorman Ph.D., CEO & Director, who commands a salary of $1,900,000.00 per year. Learn More on Matt Abernethy's salary.

How do I contact Matt Abernethy?

The corporate mailing address for Mr. Abernethy and other Neurocrine Biosciences executives is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. Neurocrine Biosciences can also be reached via phone at (858) 617-7600 and via email at [email protected]. Learn More on Matt Abernethy's contact information.

Has Matt Abernethy been buying or selling shares of Neurocrine Biosciences?

Matt Abernethy has not been actively trading shares of Neurocrine Biosciences within the last three months. Most recently, Matt Abernethy sold 1,352 shares of the business's stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $132.85, for a transaction totalling $179,613.20. Following the completion of the sale, the chief financial officer now directly owns 31,528 shares of the company's stock, valued at $4,188,494.80. Learn More on Matt Abernethy's trading history.

Who are Neurocrine Biosciences' active insiders?

Neurocrine Biosciences' insider roster includes Matt Abernethy (CFO), Eric Benevich (Insider), David Boyer (Insider), Julie Cooke (Insider), Ingrid Delaet (Insider), Kyle Gano (Insider), Kevin Gorman (CEO), Dimitri Grigoriadis (Insider), Darin Lippoldt (Insider), Malcolm Lloyd-Smith (Insider), Gary Lyons (Director), Jude Onyia (Insider), Richard Pops (Director), William Rastetter (Director), Eiry Roberts (Insider), and Stephen Sherwin (Director). Learn More on Neurocrine Biosciences' active insiders.

Are insiders buying or selling shares of Neurocrine Biosciences?

During the last year, insiders at the sold shares 47 times. They sold a total of 500,477 shares worth more than $64,680,554.88. The most recent insider tranaction occured on March, 21st when insider Ingrid Delaet sold 5,000 shares worth more than $725,300.00. Insiders at Neurocrine Biosciences own 4.6% of the company. Learn More about insider trades at Neurocrine Biosciences.

Information on this page was last updated on 3/21/2024.

Matt Abernethy Insider Trading History at Neurocrine Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2024Sell1,352$132.85$179,613.2031,528View SEC Filing Icon  
2/8/2024Sell980$134.21$131,525.8030,314View SEC Filing Icon  
2/6/2024Sell1,280$142.19$182,003.2029,434View SEC Filing Icon  
1/31/2024Sell1,283$140.72$180,543.7628,284View SEC Filing Icon  
8/21/2023Sell2,132$107.39$228,955.4827,131View SEC Filing Icon  
2/7/2023Sell26,328$102.40$2,695,987.2024,333View SEC Filing Icon  
1/31/2023Sell1,283$109.98$141,104.3421,357View SEC Filing Icon  
2/7/2022Sell3,310$80.79$267,414.90View SEC Filing Icon  
12/1/2021Sell1,645$82.59$135,860.55View SEC Filing Icon  
2/8/2021Sell2,910$116.82$339,946.2013,043View SEC Filing Icon  
12/1/2020Sell1,645$94.66$155,715.7011,494View SEC Filing Icon  
5/7/2020Sell15,000$110.21$1,653,150.0020,953View SEC Filing Icon  
4/28/2020Sell1,741$102.49$178,435.095,953View SEC Filing Icon  
2/7/2020Sell2,030$103.35$209,800.505,701View SEC Filing Icon  
12/2/2019Sell1,645$116.33$191,362.85View SEC Filing Icon  
12/3/2018Sell1,178$90.00$106,020.001,947View SEC Filing Icon  
See Full Table

Matt Abernethy Buying and Selling Activity at Neurocrine Biosciences

This chart shows Matt Abernethy's buying and selling at Neurocrine Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neurocrine Biosciences Company Overview

Neurocrine Biosciences logo
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $132.99
Low: $131.49
High: $135.17

50 Day Range

MA: $136.45
Low: $130.40
High: $143.74

2 Week Range

Now: $132.99
Low: $89.04
High: $148.37

Volume

1,033,219 shs

Average Volume

854,839 shs

Market Capitalization

$13.23 billion

P/E Ratio

54.95

Dividend Yield

N/A

Beta

0.25